non-small-cell-lung-cancer

Knowledge-graph topic · documents ABOUT non-small-cell-lung-cancer across the archive

1,034Documents about non-small-cell-lung-cancer

Documents about non-small-cell-lung-cancer

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC#390912ClinicalTrials.gov
Metabolite Profiling and Network Pharmacology of Persimmon Vinegar (Diospyros kaki) Compounds, with in silico Validation for Non-Small Cell Lung Cancer Therapy.#796612NCBI PubMed Central
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib#807369ClinicalTrials.gov
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2#811995ClinicalTrials.gov
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients#825344ClinicalTrials.gov
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers#806495ClinicalTrials.gov
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies#812777ClinicalTrials.gov
Additional file 2 of Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer#478450Figshare
Additional file 1 of Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer#478451Figshare
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.#201768ClinicalTrials.gov
Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!#178212HAL (France)
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)#238110ClinicalTrials.gov
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors#123471ClinicalTrials.gov
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors#180367ClinicalTrials.gov
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors#837331ClinicalTrials.gov
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer#4488Europe PMC
Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC#174860ClinicalTrials.gov
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy#268002ClinicalTrials.gov
Development of an Artificial Intelligence Web Application for Predicting Chemotherapy-Induced Neutropenia in Patients With Non-Small Cell Lung Cancer: A Prospective Study.#275463NCBI PubMed Central
Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26.#275736NCBI PubMed Central
EGFR Exon 20 Insertion–Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions#306093Springer Nature OA
Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer.#382576NCBI PubMed Central
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC#426792ClinicalTrials.gov
Multimodal profiling for prediction of primary resistance to anti-PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers study#429584bioRxiv / medRxiv
Noninvasive prediction of ALK fusion status in non-small cell lung cancer by a machine learning model combining CT images and clinical information.#685629NCBI PubMed Central
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC#825150ClinicalTrials.gov
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors#825504ClinicalTrials.gov
Molecular Profiling Project#835935ClinicalTrials.gov
Brain Metabolic Activity Measured by [ 18 F]FDG PET/CT Predicts Survival in Patients with Advanced Non–Small Cell Lung Cancer#159306HAL (France)
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC#811997ClinicalTrials.gov
A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors#832218ClinicalTrials.gov
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors#833361ClinicalTrials.gov
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors#807021ClinicalTrials.gov
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges#839156ClinicalTrials.gov
Expression and clinical significance of LncRNA CRNDE, XIAP, and XAF1 in non-small cell lung cancer#357071Figshare
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies#256861ClinicalTrials.gov
Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma#651621eScholarship
Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer Patients#810970ClinicalTrials.gov
Functional restoration of conformational (R175H) and contact (R273H) mutant p53 by Bacillus-derived Hydroxymycotrienin A in non-small cell lung cancer: a computational approach.#439109NCBI PubMed Central
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer#450645S-Space: Seoul National University
A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive#467584ClinicalTrials.gov
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion#807165ClinicalTrials.gov
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib#811539ClinicalTrials.gov
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer#429755ClinicalTrials.gov
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.#373613ClinicalTrials.gov
Image 3_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367121Figshare
Image 4_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367122Figshare
Image 1_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367123Figshare
Image 2_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367124Figshare
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)#827772ClinicalTrials.gov

Topic record · derived from the Conceptio knowledge graph (shared subject terms across the corpus)
Conceptio Open Knowledge Archive — topic hubs link to canonical document pages with full provenance.